601 related articles for article (PubMed ID: 19104176)
1. Pharmacokinetic-pharmacodynamic model for the reversal of neuromuscular blockade by sugammadex.
Ploeger BA; Smeets J; Strougo A; Drenth HJ; Ruigt G; Houwing N; Danhof M
Anesthesiology; 2009 Jan; 110(1):95-105. PubMed ID: 19104176
[TBL] [Abstract][Full Text] [Related]
2. Early reversal of profound rocuronium-induced neuromuscular blockade by sugammadex in a randomized multicenter study: efficacy, safety, and pharmacokinetics.
Sparr HJ; Vermeyen KM; Beaufort AM; Rietbergen H; Proost JH; Saldien V; Velik-Salchner C; Wierda JM
Anesthesiology; 2007 May; 106(5):935-43. PubMed ID: 17457124
[TBL] [Abstract][Full Text] [Related]
3. A temporary decrease in twitch response during reversal of rocuronium-induced muscle relaxation with a small dose of sugammadex.
Eleveld DJ; Kuizenga K; Proost JH; Wierda JM
Anesth Analg; 2007 Mar; 104(3):582-4. PubMed ID: 17312212
[TBL] [Abstract][Full Text] [Related]
4. Reversal of profound, high-dose rocuronium-induced neuromuscular blockade by sugammadex at two different time points: an international, multicenter, randomized, dose-finding, safety assessor-blinded, phase II trial.
Pühringer FK; Rex C; Sielenkämper AW; Claudius C; Larsen PB; Prins ME; Eikermann M; Khuenl-Brady KS
Anesthesiology; 2008 Aug; 109(2):188-97. PubMed ID: 18648227
[TBL] [Abstract][Full Text] [Related]
5. Reversal of neuromuscular blockade by sugammadex after continuous infusion of rocuronium in patients randomized to sevoflurane or propofol maintenance anesthesia.
Rex C; Wagner S; Spies C; Scholz J; Rietbergen H; Heeringa M; Wulf H
Anesthesiology; 2009 Jul; 111(1):30-5. PubMed ID: 19512873
[TBL] [Abstract][Full Text] [Related]
6. Cochrane corner: sugammadex, a selective reversal medication for preventing postoperative residual neuromuscular blockade.
Abrishami A; Ho J; Wong J; Yin L; Chung F
Anesth Analg; 2010 Apr; 110(4):1239. PubMed ID: 20357160
[TBL] [Abstract][Full Text] [Related]
7. Sugammadex reversal of rocuronium-induced neuromuscular blockade: a comparison with neostigmine-glycopyrrolate and edrophonium-atropine.
Sacan O; White PF; Tufanogullari B; Klein K
Anesth Analg; 2007 Mar; 104(3):569-74. PubMed ID: 17312210
[TBL] [Abstract][Full Text] [Related]
8. Sugammadex provides faster reversal of vecuronium-induced neuromuscular blockade compared with neostigmine: a multicenter, randomized, controlled trial.
Khuenl-Brady KS; Wattwil M; Vanacker BF; Lora-Tamayo JI; Rietbergen H; Alvarez-Gómez JA
Anesth Analg; 2010 Jan; 110(1):64-73. PubMed ID: 19713265
[TBL] [Abstract][Full Text] [Related]
9. Reversal of rocuronium-induced neuromuscular blockade with sugammadex in pediatric and adult surgical patients.
Plaud B; Meretoja O; Hofmockel R; Raft J; Stoddart PA; van Kuijk JH; Hermens Y; Mirakhur RK
Anesthesiology; 2009 Feb; 110(2):284-94. PubMed ID: 19194156
[TBL] [Abstract][Full Text] [Related]
10. Reversal of rocuronium-induced (1.2 mg/kg) profound neuromuscular block by sugammadex: a multicenter, dose-finding and safety study.
de Boer HD; Driessen JJ; Marcus MA; Kerkkamp H; Heeringa M; Klimek M
Anesthesiology; 2007 Aug; 107(2):239-44. PubMed ID: 17667567
[TBL] [Abstract][Full Text] [Related]
11. The effect of residual neuromuscular blockade on the speed of reversal with sugammadex.
White PF; Tufanogullari B; Sacan O; Pavlin EG; Viegas OJ; Minkowitz HS; Hudson ME
Anesth Analg; 2009 Mar; 108(3):846-51. PubMed ID: 19224792
[TBL] [Abstract][Full Text] [Related]
12. Sugammadex in clinical practice.
Mirakhur RK
Anaesthesia; 2009 Mar; 64 Suppl 1():45-54. PubMed ID: 19222431
[TBL] [Abstract][Full Text] [Related]
13. Sugammadex--a short review and clinical recommendations for the cardiac anesthesiologist.
Hemmerling TM; Zaouter C; Geldner G; Nauheimer D
Ann Card Anaesth; 2010; 13(3):206-16. PubMed ID: 20826961
[TBL] [Abstract][Full Text] [Related]
14. Reversal of profound neuromuscular block by sugammadex administered three minutes after rocuronium: a comparison with spontaneous recovery from succinylcholine.
Lee C; Jahr JS; Candiotti KA; Warriner B; Zornow MH; Naguib M
Anesthesiology; 2009 May; 110(5):1020-5. PubMed ID: 19387176
[TBL] [Abstract][Full Text] [Related]
15. Preclinical pharmacology of sugammadex.
Bom A; Hope F; Rutherford S; Thomson K
J Crit Care; 2009 Mar; 24(1):29-35. PubMed ID: 19272536
[TBL] [Abstract][Full Text] [Related]
16. Clinical implications of sugammadex.
Caldwell JE; Miller RD
Anaesthesia; 2009 Mar; 64 Suppl 1():66-72. PubMed ID: 19222433
[TBL] [Abstract][Full Text] [Related]
17. Assessment of the potential for displacement interactions with sugammadex: a pharmacokinetic-pharmacodynamic modelling approach.
Zwiers A; van den Heuvel M; Smeets J; Rutherford S
Clin Drug Investig; 2011; 31(2):101-11. PubMed ID: 21067251
[TBL] [Abstract][Full Text] [Related]
18. Sugammadex: another milestone in clinical neuromuscular pharmacology.
Naguib M
Anesth Analg; 2007 Mar; 104(3):575-81. PubMed ID: 17312211
[TBL] [Abstract][Full Text] [Related]
19. Sugammadex efficacy for reversal of rocuronium- and vecuronium-induced neuromuscular blockade: A pooled analysis of 26 studies.
Herring WJ; Woo T; Assaid CA; Lupinacci RJ; Lemmens HJ; Blobner M; Khuenl-Brady KS
J Clin Anesth; 2017 Sep; 41():84-91. PubMed ID: 28802619
[TBL] [Abstract][Full Text] [Related]
20. Neuromuscular transmission: new concepts and agents.
de Boer HD
J Crit Care; 2009 Mar; 24(1):36-42. PubMed ID: 19272537
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
